

This article was downloaded by:

On: 26 January 2011

Access details: Access Details: Free Access

Publisher Taylor & Francis

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



## Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713597286>

### Synthesis of *N*-Glycosylated Pyridines as New Antiviral Agents

E. S. Ibrahim<sup>a</sup>; G. E. H. Elgemeie<sup>abc</sup>; M. M. Abbasi<sup>d</sup>; Y. A. Abbas<sup>e</sup>; M. A. Elbadawi<sup>d</sup>; A. M. E. Attia<sup>e</sup>

<sup>a</sup> Chemistry Department, Faculty of Science, Suez Canal University, Egypt <sup>b</sup> Chemistry Department, Faculty of Science, Cairo University (Bani Suef Branch), Egypt <sup>c</sup> Chemistry Department, Faculty of Science, Qatar University, Doha, State of Qatar <sup>d</sup> Chemistry Department, Faculty of Science, Tanta University, Egypt <sup>e</sup> Chemistry Department, Faculty of Education, Tanta University (Kafr El-Sheikh), Egypt

**To cite this Article** Ibrahim, E. S. , Elgemeie, G. E. H. , Abbasi, M. M. , Abbas, Y. A. , Elbadawi, M. A. and Attia, A. M. E.(1995) 'Synthesis of *N*-Glycosylated Pyridines as New Antiviral Agents', *Nucleosides, Nucleotides and Nucleic Acids*, 14: 6, 1415 – 1423

**To link to this Article:** DOI: 10.1080/15257779508010701

**URL:** <http://dx.doi.org/10.1080/15257779508010701>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

## SYNTHESIS OF *N*-GLYCOSYLATED PYRIDINES AS NEW ANTIVIRAL AGENTS

E.S. Ibrahim<sup>a</sup>, G.E.H. Elgemeie<sup>a,†,b</sup>, M.M. Abbasi<sup>c</sup>, Y.A. Abbas<sup>d</sup>, M.A. Elbadawi<sup>c</sup> and A.M.E. Attia<sup>d</sup>.

<sup>a</sup>Chemistry Department, Faculty of Science, Suez Canal University, Egypt

<sup>b</sup>Chemistry Department, Faculty of Science, Cairo University (Bani Suef Branch), Egypt

<sup>c</sup>Chemistry Department, Faculty of Science, Tanta University, Egypt



<sup>d</sup>Chemistry Department, Faculty of Education, Tanta University (Kafr El-Sheikh), Egypt

**Abstract:** A series of 3-cyanopyridine glycosides have been synthesized and evaluated for their inhibitory activity against human immunodeficiency virus (HIV) replication in MT-4 cells. Among the 3-cyanopyridine glycosides 6-(*p*-methylphenyl) and 6-(*p*-aminophenyl) were the most selective inhibitors of HIV replication.

3-Deazauridine and 3-deazacytidine were found to exert marked inhibitory effects on the growth of neoplastic and bacterial culture<sup>1</sup> and also have antiviral activity against RNA viruses<sup>2</sup>. Also 3-deazauridine apparently blocks the action of an enzyme which catalyzes overall amination of UTP to CTP<sup>3</sup>. The 3-deazapyrimidine nucleosides constitute another logical class of analogues with potential biological activity<sup>4,5</sup>. As a part of our program directed for development of new, simple and efficient procedures for the synthesis of antimetabolites<sup>6-11</sup>, we report in this paper a novel synthesis of 3-deazapyrimidine glycosides **5** utilizing our previously reported pyridine-2(1*H*)-ones **3**<sup>12</sup> as starting materials. Compounds **3** can be prepared by the reaction of  $\alpha$ ,  $\beta$ -unsaturated nitriles **1** with acetophenones **2** in boiling ethanol containing ammonium acetate. Compounds **3** reacted with 2,3,4,6-tetra-*O*-acetyl- $\alpha$ -D-glucosyl- and galactopyranosyl bromides **4** in the presence of aqueous potassium hydroxide to give the corresponding *N*-glucosides **5a-h** and *N*-galactosides **5i-p**, respectively. The structures of the reaction products **5** were established and confirmed on the basis of their elemental analyses and spectral data (MS, IR, <sup>1</sup>H NMR, <sup>13</sup>C NMR). Thus the analytical data for **5n** revealed a molecular formula C<sub>31</sub>H<sub>30</sub>N<sub>2</sub>O<sub>11</sub> (*m/z* 606). The <sup>1</sup>H NMR spectrum showed a doublet at  $\delta$  6.6 ppm assigned to the anomeric proton of the galactose moiety with a spin-spin

---

<sup>†</sup> Present Address: Chemistry Department, Faculty of Science, Qatar University, P.O.Box 2713, Doha, State of Qatar.



|           | Ar      | R <sup>1</sup>   | R <sup>2</sup> | R <sup>3</sup> |           | Ar      | R <sup>1</sup>   | R <sup>2</sup> | R <sup>3</sup> |
|-----------|---------|------------------|----------------|----------------|-----------|---------|------------------|----------------|----------------|
| <b>5a</b> | Phenyl  | H                | OAc            | H              | <b>6a</b> | Phenyl  | H                | OH             | H              |
| <b>b</b>  | Phenyl  | CH <sub>3</sub>  | OAc            | H              | <b>b</b>  | Phenyl  | CH <sub>3</sub>  | OH             | H              |
| <b>c</b>  | Phenyl  | OCH <sub>3</sub> | OAc            | H              | <b>c</b>  | Phenyl  | OCH <sub>3</sub> | OH             | H              |
| <b>d</b>  | Phenyl  | NH <sub>2</sub>  | OAc            | H              | <b>d</b>  | Phenyl  | NH <sub>2</sub>  | OH             | H              |
| <b>e</b>  | 2-Furyl | H                | OAc            | H              | <b>e</b>  | 2-Furyl | H                | OH             | H              |
| <b>f</b>  | 2-Furyl | CH <sub>3</sub>  | OAc            | H              | <b>f</b>  | 2-Furyl | CH <sub>3</sub>  | OH             | H              |
| <b>g</b>  | 2-Furyl | OCH <sub>3</sub> | OAc            | H              | <b>g</b>  | 2-Furyl | OCH <sub>3</sub> | OH             | H              |
| <b>h</b>  | 2-Furyl | NH <sub>2</sub>  | OAc            | H              | <b>h</b>  | 2-Furyl | NH <sub>2</sub>  | OH             | H              |
| <b>i</b>  | Phenyl  | H                | H              | OAc            | <b>i</b>  | Phenyl  | H                | H              | OH             |
| <b>j</b>  | Phenyl  | CH <sub>3</sub>  | H              | OAc            | <b>j</b>  | Phenyl  | CH <sub>3</sub>  | H              | OH             |
| <b>k</b>  | Phenyl  | OCH <sub>3</sub> | H              | OAc            | <b>k</b>  | Phenyl  | OCH <sub>3</sub> | H              | OH             |
| <b>l</b>  | Phenyl  | NH <sub>2</sub>  | H              | OAc            | <b>l</b>  | Phenyl  | NH <sub>2</sub>  | H              | OH             |
| <b>m</b>  | 2-Furyl | H                | H              | OAc            | <b>m</b>  | 2-Furyl | H                | H              | OH             |
| <b>n</b>  | 2-Furyl | CH <sub>3</sub>  | H              | OAc            | <b>n</b>  | 2-Furyl | CH <sub>3</sub>  | H              | OH             |
| <b>o</b>  | 2-Furyl | OCH <sub>3</sub> | H              | OAc            | <b>o</b>  | 2-Furyl | OCH <sub>3</sub> | H              | OH             |
| <b>p</b>  | 2-Furyl | NH <sub>2</sub>  | H              | OAc            | <b>p</b>  | 2-Furyl | NH <sub>2</sub>  | H              | OH             |

**Table 1:** Comparative potency and selectivity of 3-cyanopyridine-2-one glucosides and galactosides analogues as inhibitors of HIV replication in MT-4 cells.

| Compd | EC <sub>50</sub> <sup>a</sup><br>μM | IC <sub>50</sub> <sup>b</sup><br>μM | TI <sup>c</sup><br>(ratio IC <sub>50</sub> /EC <sub>50</sub> ) |
|-------|-------------------------------------|-------------------------------------|--|
| 5a    |                                     | > 16.5                              |  |
| 5b    |                                     | > 11.7                              |  |
| 5c    |                                     | > 15.8                              |  |
| 5d    |                                     | > 11.6                              |  |
| 5e    |                                     | > 16.8                              |  |
| 5f    |                                     | > 8.6                               |  |
| 5g    |                                     | > 11.6                              |  |
| 5h    | 11.7                                | > 11.8                              | > 1  |
| 5j    |                                     | > 16.5                              |  |
| 5k    |                                     | > 11.4                              |  |
| 5m    |                                     | > 11.9                              |  |
| 5n    |                                     | > 16.4                              |  |
| 5o    |                                     | > 11.6                              |  |
| 6a    |                                     | > 21.4                              |  |
| 6f    | 8.03                                | > 82.1                              | > 10.2   |
| 6i    |                                     | > 59.9                              |  |
| 6j    | 18.6                                | > 22.3                              | > 1.2  |
| 6k    |                                     | > 21.5                              |  |

- a. Approximate values for 50% effective concentration of MT-4 cells against the cytopathic effect of HIV (EC<sub>50</sub>)
- b. Inhibitor concentration for 50% (IC<sub>50</sub>).
- c. Therapeutic index TI (IC<sub>50</sub>/EC<sub>50</sub>).

coupling constant equal to 8.9 Hz which corresponds to a diaxial orientation for the H-1' and H-2' protons indicating the presence of only β-configuration. The other six protons of the galactopyranosyl ring resonate in the δ 4.12-5.64 ppm region. The remaining four acetoxy groups appeared as four singlets at δ 1.78-2.18 ppm region, while the methyl group of the aglycone resonated at δ 2.41 ppm. The <sup>13</sup>C NMR spectrum of 5n was characterized by a signal at δ 87.1 ppm corresponding to the C-1' atom of the β-D-galactopyranose. Four signals appeared at δ 170.5-169.4 ppm due to the four acetoxy carbonyl carbon atoms of galactose, while a signal appearing at δ 20.33-20.26 ppm was attributed to the galactose methyl carbons. Another five

**Table 2:** Physical and analytical data for compounds **5a-p** and **6a-p**.

| Compd.    | MP<br>°C | Yield<br>% | Mol. formula                     | Found/Calcd. (%) |     |     | m/z |
|-----------|----------|------------|----------------------------------|------------------|-----|-----|-----|
|           |          |            |                                  | C                | H   | N   |     |
| <b>5a</b> | 180      | 74         | $C_{32}H_{30}N_2O_{10}$<br>(602) | 63.9             | 5.1 | 4.6 | 602 |
|           |          |            |                                  | 63.8             | 5.0 | 4.7 |     |
| <b>5b</b> | 196      | 76         | $C_{33}H_{32}N_2O_{10}$<br>(616) | 64.6             | 5.1 | 4.7 | 616 |
|           |          |            |                                  | 64.3             | 5.2 | 4.5 |     |
| <b>5c</b> | 192      | 73         | $C_{33}H_{32}N_2O_{11}$<br>(632) | 62.9             | 5.3 | 4.5 | 632 |
|           |          |            |                                  | 62.7             | 5.1 | 4.4 |     |
| <b>5d</b> | 177      | 70         | $C_{32}H_{31}N_3O_{10}$<br>(617) | 62.5             | 5.2 | 6.9 | 617 |
|           |          |            |                                  | 62.2             | 5.0 | 6.8 |     |
| <b>5e</b> | 222      | 71         | $C_{30}H_{28}N_2O_{11}$<br>(592) | 61.0             | 4.8 | 4.9 | 592 |
|           |          |            |                                  | 60.8             | 4.7 | 4.7 |     |
| <b>5f</b> | 206      | 75         | $C_{31}H_{30}N_2O_{11}$<br>(606) | 61.5             | 4.9 | 4.8 | 606 |
|           |          |            |                                  | 61.4             | 5.0 | 4.6 |     |
| <b>5g</b> | 190      | 70         | $C_{31}H_{30}N_2O_{12}$<br>(622) | 60.0             | 4.8 | 4.7 | 622 |
|           |          |            |                                  | 59.8             | 4.8 | 4.5 |     |
| <b>5h</b> | 226      | 67         | $C_{30}H_{29}N_3O_{11}$<br>(607) | 59.4             | 4.9 | 7.1 | 607 |
|           |          |            |                                  | 59.3             | 4.8 | 6.9 |     |
| <b>5i</b> | 146      | 72         | $C_{32}H_{30}N_2O_{10}$<br>(602) | 64.0             | 4.8 | 4.5 |     |
|           |          |            |                                  | 63.8             | 5.0 | 4.7 |     |
| <b>5j</b> | 183      | 74         | $C_{33}H_{32}N_2O_{10}$<br>(616) | 64.1             | 5.2 | 4.4 | 616 |
|           |          |            |                                  | 64.3             | 5.2 | 4.5 |     |
| <b>5k</b> | 168      | 71         | $C_{33}H_{32}N_2O_{11}$<br>(632) | 62.9             | 5.2 | 4.1 | 632 |
|           |          |            |                                  | 62.7             | 5.1 | 4.4 |     |
| <b>5l</b> | 105      | 68         | $C_{32}H_{31}N_3O_{10}$<br>(617) | 62.1             | 5.1 | 7.0 |     |
|           |          |            |                                  | 62.2             | 5.0 | 6.8 |     |
| <b>5m</b> | 180      | 70         | $C_{30}H_{28}N_2O_{11}$<br>(592) | 60.9             | 4.6 | 4.5 | 592 |
|           |          |            |                                  | 60.8             | 4.7 | 4.7 |     |
| <b>5n</b> | 220      | 73         | $C_{31}H_{30}N_2O_{11}$<br>(606) | 61.6             | 5.0 | 4.6 | 606 |
|           |          |            |                                  | 61.4             | 5.0 | 4.6 |     |
| <b>5o</b> | 210      | 69         | $C_{31}H_{30}N_2O_{12}$<br>(622) | 59.9             | 4.9 | 4.6 |     |
|           |          |            |                                  | 59.8             | 4.8 | 4.5 |     |
| <b>5p</b> | 170      | 65         | $C_{30}H_{29}N_3O_{11}$<br>(607) | 59.6             | 5.0 | 6.9 |     |
|           |          |            |                                  | 59.3             | 4.8 | 6.9 |     |
| <b>6a</b> | 296      | 83         | $C_{24}H_{22}N_2O_6$<br>(434)    | 66.6             | 5.0 | 6.7 | 434 |
|           |          |            |                                  | 66.4             | 5.1 | 6.5 |     |

Table 2. (Continued)

|           |     |    |                               |      |     |     |     |
|-----------|-----|----|-------------------------------|------|-----|-----|-----|
| <b>6b</b> | 263 | 85 | $C_{23}H_{24}N_2O_6$<br>(448) | 67.2 | 5.4 | 6.5 | 448 |
|           |     |    |                               | 67.0 | 5.4 | 6.3 |     |
| <b>6c</b> | 256 | 84 | $C_{23}H_{24}N_2O_7$<br>(464) | 64.5 | 5.3 | 6.3 | 464 |
|           |     |    |                               | 64.7 | 5.2 | 6.0 |     |
| <b>6d</b> | 180 | 83 | $C_{24}H_{23}N_3O_6$<br>(449) | 64.3 | 5.1 | 9.2 |     |
|           |     |    |                               | 64.1 | 5.1 | 9.4 |     |
| <b>6e</b> | 295 | 84 | $C_{22}H_{20}N_2O_7$<br>(424) | 62.4 | 4.5 | 6.8 | 424 |
|           |     |    |                               | 62.3 | 4.7 | 6.6 |     |
| <b>6f</b> | 297 | 85 | $C_{23}H_{22}N_2O_7$<br>(438) | 63.1 | 5.0 | 6.3 | 438 |
|           |     |    |                               | 63.0 | 5.0 | 6.4 |     |
| <b>6g</b> | 285 | 81 | $C_{23}H_{22}N_2O_8$<br>(454) | 60.6 | 4.9 | 6.5 |     |
|           |     |    |                               | 60.8 | 4.8 | 6.2 |     |
| <b>6h</b> | 190 | 83 | $C_{22}H_{21}N_3O_7$<br>(439) | 60.0 | 4.8 | 9.7 | 439 |
|           |     |    |                               | 60.1 | 4.8 | 9.6 |     |
| <b>6i</b> | 287 | 84 | $C_{24}H_{22}N_2O_6$<br>(434) | 66.5 | 5.3 | 6.6 |     |
|           |     |    |                               | 66.4 | 5.1 | 6.5 |     |
| <b>6j</b> | 261 | 85 | $C_{23}H_{24}N_2O_6$<br>(448) | 66.9 | 5.4 | 6.5 | 448 |
|           |     |    |                               | 67.0 | 5.4 | 6.3 |     |
| <b>6k</b> | 264 | 82 | $C_{23}H_{24}N_2O_7$<br>(464) | 64.6 | 5.4 | 6.1 |     |
|           |     |    |                               | 64.7 | 5.2 | 6.0 |     |
| <b>6l</b> | 173 | 84 | $C_{24}H_{23}N_3O_6$<br>(449) | 64.2 | 5.3 | 9.5 | 449 |
|           |     |    |                               | 64.1 | 5.1 | 9.4 |     |
| <b>6m</b> | 288 | 83 | $C_{22}H_{20}N_2O_7$<br>(424) | 62.5 | 4.6 | 6.8 | 424 |
|           |     |    |                               | 62.3 | 4.7 | 6.6 |     |
| <b>6n</b> | 285 | 84 | $C_{23}H_{22}N_2O_7$<br>(438) | 63.2 | 5.2 | 6.6 | 438 |
|           |     |    |                               | 63.0 | 5.0 | 6.4 |     |
| <b>6o</b> | 290 | 82 | $C_{23}H_{22}N_2O_8$<br>(454) | 60.9 | 4.9 | 6.4 | 454 |
|           |     |    |                               | 60.8 | 4.8 | 6.2 |     |
| <b>6p</b> | 288 | 84 | $C_{22}H_{21}N_3O_7$<br>(439) | 60.3 | 5.0 | 9.5 |     |
|           |     |    |                               | 60.1 | 4.8 | 9.6 |     |

**Table 3:** Spectral data for selected compounds listed in Table 2.

| Compd.    | IR(KBr)/cm <sup>-1</sup>   | <sup>1</sup> H NMR (DMSO) $\delta$ /ppm   |
|-----------|--|---|
| <b>5a</b> | 2220 (CN),<br>1752 (CO ester),<br>1648 (CO pyridone)                                   | 1.82-2.08 (4s, 12H, 4CH <sub>3</sub> CO), 4.21 (m, 2H, H-6',6"), 4.60 (m, 1H, H-5'), 5.32 (m, 2H, H-4' and H-3'), 5.78 (m, 1H, H-2'), 6.80 (d, $J_{1,2}$ = 8.38 Hz, 1H, H-1'), 7.73 (s, 1H, Pyridine H-5), 7.90 (s, 5H, Ar-H), 8.13 (s, 5H, Ar-H).  |
| <b>5b</b> | 2222 (CN),<br>1750 (CO ester),<br>1636 (CO pyridone)                                   | 1.76-2.10 (4s, 12H, 4CH <sub>3</sub> CO), 2.40 (s, 3H, CH <sub>3</sub> ), 4.16 (m, 2H, H-6', 6"), 4.53 (m, 1H, H-5'), 5.21 (m, 2H, H-4' and H-3'), 5.70 (t, 1H, H-2'), 6.76 (d, $J_{1,2}$ = 8.63 Hz, 1H, H-1'), 7.39 (d, 2H, Ar-H), 7.65 (s, 3H, Ar-H), 7.76 (s, 1H, pyridine H-5), 7.96 (s, 2H, Ar-H), 8.30 (d, 2H, Ar-H)                    |
| <b>5c</b> | 2218 (CN),<br>1755 (CO ester),<br>1640 (CO pyridone)                                   | 1.85-2.12 (4s, 12H, 4CH <sub>3</sub> CO), 3.90 (s, 3H, OCH <sub>3</sub> ), 4.19 (m, 2H, H-6', 6"), 4.56 (t, 1H, H-5'), 5.18 (m, 2H, H-4' and H-3'), 5.70 (d, 1H, H-2'), 6.65 (d, $J_{1,2}$ = 8.55 Hz, 1H, H-1'), 7.11 (d, 2H, Ar-H), 7.66 (s, 3H, Ar-H), 7.77 (s, 1H, pyridine H-5), 7.95 (s, 2H, Ar-H), 8.30 (d, 2H, Ar-H).                  |
| <b>5d</b> | 3460, 3380 (NH <sub>2</sub> ),<br>2220 (CN),<br>1750(CO ester),<br>1642(CO pyridone)   | 1.88-2.09 (4s, 12H, 4CH <sub>3</sub> CO), 4.25 (m, 2H, H-6',6"), 4.60 (m, 1H, H-5'), 5.28 (m, 2H, H-4' and H-3'), 5.80 (t, 1H, H-2'), 6.00 (s, 2H, NH <sub>2</sub> ), 6.70 (d, $J_{1,2}$ = 8.35 Hz, 1H, H-1'), 7.64 (s, 5H, Ar-H), 7.71 (s, 1H, pyridine H-5), 8.23 (d, 4H, Ar-H).  |
| <b>5e</b> | 2220 (CN),<br>1756 (CO ester),<br>1610 (CO pyridone)                                   | 1.67-2.11 (4s, 12H, 4CH <sub>3</sub> CO), 4.12 (d, 2H, H-6',6"), 4.31 (m, 1H, H-5'), 5.32 (m, 2H, H-4' and H-3'), 5.51 (m, 1H, H-2'), 6.38 (d, $J_{1,2}$ = 8.46 Hz, 1H, H-1'), 6.72 (s, 1H, furan H-4), 7.58 (s, 5H, Ar-H), 7.71 (s, 1H, pyridine H-5), 8.03 (s, 1H, furan H-3), 8.18 (s, 1H, furan H-5).                                     |
| <b>5f</b> | 2222 (CN),<br>1750 (CO ester),<br>1600 (CO pyridone)                                   | 1.64-2.05 (4s, 12H, 4CH <sub>3</sub> CO), 2.46 (s,3H, CH <sub>3</sub> ), 4.08 (m, 2H, H-6',6" and 1H, H-5'), 4.36 (m, 1H, H-4'), 5.34 (m, 2H, H-3' and H-2'), 6.32 (d, $J_{1,2}$ = 8.64 Hz, 1H, H-1'), 6.70 (s, 1H, furan H-4), 7.41 (d, 4H, Ar-H), 7.69 (s, 1H, pyridine H-5), 7.80 (s, 1H, furan H-3), 8.00 (d, 1H, furan H-5).             |
| <b>5g</b> | 2218 (CN),<br>1752 (CO ester),<br>1610 (CO pyridone)                                   | 1.62-2.10 (4s, 12H, 4CH <sub>3</sub> CO), 3.88 (s, 3H, OCH <sub>3</sub> ), 4.05 (m, 2H, H-6',6" and 1H, H-5'), 4.34 (m, 1H, H-4'), 5.30 (t, 1H, H-3'), 5.48 (m, 1H, H-2'), 6.31 (d, $J_{1,2}$ = 8.66 Hz, 1H, H-1'), 6.62 (s, 1H, furan H-4), 7.10 (d, 4H, Ar-H), 7.67 (s, 1H, pyridine H-5), 7.94 (s, 1H, furan H-3), 8.16 (d, 1H, furan H-5) |
| <b>5h</b> | 3460, 3360 (NH <sub>2</sub> ),<br>2220 (CN),<br>1760 (CO ester),<br>1610 (CO pyridone) | 1.94-2.16 (4s, 12H, 4CH <sub>3</sub> CO), 4.23 (m, 2H, H-6', 6"), 4.51 (s, 1H, H-5'), 5.22 (m, 2H, H-4' and H-3'), 5.72 (t, 1H, H-2'), 6.00 (s, 2H, NH <sub>2</sub> ), 6.70 (d, $J_{1,2}$ = 8.56 Hz, 1H, H-1'), 6.85 (s, 1H, furan H-4), 7.80 (d, 4H, Ar-H), 7.73 (s, 1H, pyridine H-5), 7.91 (s, 1H, furan H-3), 8.10 (s, 1H, furan H-5).    |
| <b>5i</b> | 2220 (CN),<br>1760 (CO ester),<br>1650 (CO pyridone)                                   | 1.86-2.12 (4s, 12H, 4CH <sub>3</sub> CO), 4.21 (m, 2H, H-6', 6"), 4.63 (m, 1H, H-5'), 5.44 (m, 2H, H-4' and H-3'), 5.60 (t, 1H, H-2'), 6.61 (d, $J_{1,2}$ = 8.38 Hz, 1H, H-1'), 6.90 (s, 1H, furan H-4), 7.65 (s, 5H, Ar-H), 7.78 (s, 1H, pyridine H-5), 8.20 (d, 1H, furan H-3), 8.41 (s, 1H, furan H-5)                                     |
| <b>5j</b> | 2222 (CN),<br>1758 (CO ester),<br>1650 (CO pyridone)                                   | 1.75-2.15 (4s, 12H, 4CH <sub>3</sub> CO), 2.40 (s, 3H, CH <sub>3</sub> ), 4.15 (m, 2H, H-6',6" and 1H, H-5'), 4.65 (t, 1H, H-4'), 5.57 (m, 2H, H-3' and H-2'), 6.65 (d, $J_{1,2}$ = 8.71 Hz, 1H, H-1'), 6.85 (s, 1H, furan H-4), 7.35 (d, 4H, Ar-H), 7.75 (d, 1H, furan H-3), 8.10 (s, 1H, pyridine H-5), 8.34 (d, 1H, furan H-5).            |
| <b>5m</b> | 2218 (CN),<br>1754 (CO ester),<br>1650 (CO pyridone)                                   | 1.86-2.16 (4s, 12H, 4CH <sub>3</sub> CO), 4.22 (m, 2H, H-6',6"), 4.64 (m, 1H, H-5'), 5.41 (m, 2H, H-4' and H-3'), 5.60 (t, 1H, H-2'), 6.58 (d, $J_{1,2}$ = 8.68 Hz, 1H, H-1'), 6.88 (s, 1H, furan H-4), 7.65 (s, 5H, Ar-H), 7.76 (s, 1H, pyridine H-5), 8.20 (d, 1H, furan H-3), 8.34 (s, 1H, furan H-5).                                     |

Table 3: (Continued)

|           |   |   |
|-----------|---|---|
| <b>5a</b> | 2220 (CN),<br>1760 (CO ester),<br>1650 (CO pyridone)                  | 1.78-2.18 (4s, 12H, 4CH <sub>3</sub> CO), 2.41 (s, 3H, CH <sub>3</sub> ), 4.12 (m, 2H, H-6', 6" and 1H, H-5'), 4.65 (t, 1H, H-4'), 5.51 (m, 2H, H-3' and H-2'), 6.60 (d, J <sub>1,2</sub> = 8.90 Hz, 1H, H-1') 6.85 9s, 1H, furan H-4), 7.32 (d, 4H, Ar-H), 7.78 (s, 1H, pyridine H-5), 8.10 (d, 1H, furan H-3), 8.33 (d, 1H, furan H-5).                                   |
| <b>6c</b> | 3600-3150 (OH),<br>2220 (CN),<br>1630 (CO pyridone)                   | 3.25-3.78 (m, 6H, H-6', 6", H-5', H-4', H-3' and H-2'), 3.88 (s, 3H, OCH <sub>3</sub> ), 4.67 (t, 1H, 2'-OH), 5.18 (d, 1H, 3'-OH), 5.24 (s, 1H, 4'-OH), 5.50 (d, 1H, 6'-OH), 6.20 (d, J <sub>1,2</sub> = 8.64 Hz, 1H, H-1'), 7.12 (d, 2H, Ar-H), 7.63 (m, 3H, Ar-H), 7.74 (m, 2H, Ar-H), 7.81 (s, 1H, pyridine H-5), 8.25 (d, 2H, Ar-H)                                     |
| <b>6d</b> | 3650-3200 (OH),<br>2222 (CN),<br>1635 (CO pyridone)                   | 3.21-3.74 (m, 6H, H-6', 6", H-5', H-4', H-3' and H-2'), 4.65 (t, 1H, 2'-OH), 5.15 (d, 1H, 3'-OH), 5.21 (s, 1H, 4'-OH), 4.45 (d, 1H, 6'-OH), 5.88 (s, 2H, NH <sub>2</sub> ), 6.18 (d, J <sub>1,2</sub> = 8.55 Hz, 1H, H-1'), 6.68 (d, 2H, Ar-H), 7.56 (m, 3H, Ar-H), 7.62 (s, 1H, pyridine H-5), 7.72 (m, 2H, Ar-H), 8.00 (d, 2H, Ar-H).                                     |
| <b>6e</b> | 3600-3180 (OH)<br>2218 (CN)<br>1610 (CO Pyridone)                     | 3.18-3.65 (m, 6H, H-6', 6", H-5', H-4', H-3' and H-2'), 4.61 (t, 1H, 2'-OH), 5.18 (d, 2H, 3'-OH and 4'-OH), 5.46 (s, 1H, 6'-OH), 6.14 (d, J <sub>1,2</sub> = 8.63 Hz, 1H, H-1'), 6.85 (dd, 1H, furan H-4), 7.54 (t, 3H, Ar-H), 7.72 (d, 1H, furan H-3), 8.08 (s, 1H, pyridine H-5), 8.11 (d, 2H, Ar-H), 8.24 (dd, 1H, furan H-5).   |
| <b>6f</b> | 3650-3150 (OH)<br>2220 (CN),<br>1610 (CO pyridone)                    | 2.32 (s, 3H, CH <sub>3</sub> ), 3.26-3.85 (m, 6H, H-6', 6", H-5', H-4', H-3' and H-2'), 4.65 (t, 1H, 2'-OH), 5.15 (d, 2H, 3'-OH and 4'-OH), 5.45 (s, 1H, 6'-OH), 6.15 (d, J <sub>1,2</sub> = 8.52 Hz, 1H, H-1'), 6.85 (m, 1H, furan H-4), 7.35 (d, 4H, Ar-H), 7.71 (d, 1H, furan H-3), 8.05 (s, 1H, pyridine H-5), 8.15 (d, 1H, furan H-5).                                 |
| <b>6g</b> | 3600-3200 (OH)<br>2222 (CN),<br>1600 (CO pyridone)                    | 3.21-3.77 (m, 6H, H-6', 6", H-5', H-4', H-3' and H-2'), 3.86 (s, 3H, OCH <sub>3</sub> ), 4.65 (s, 1H, 2'-OH), 5.20 (s, 2H, 3'-OH and 4'-OH), 5.54 s, 1H, 6'-OH), 6.18 (d, J <sub>1,2</sub> = 8.38 Hz, 1H, H-1'), 6.88 (dd, 1H, furan H-4), 7.18 (d, 2H, Ar-H), 7.65 (d, 1H, furan H-3), 8.00 (s, 1H, pyridine H-5), 8.13 (m, 1H, furan H-5), 8.21 (d, 2H, Ar-H).            |
| <b>6j</b> | 3640-3180 (OH),<br>2220 (CN),<br>1630 (CO pyridone)                   | 2.28 (s, 3H, CH <sub>3</sub> ), 3.21-3.78 (m, 6H, H-6', 6", H-5', H-4', H-3' and H-2'), 4.63 (t, 1H, 2'-OH), 5.16 (d, 1H, 3'-OH), 5.21 (s, 1H, 4'-OH), 5.42 (d, 1H, 6'-OH), 6.18 (d, J <sub>1,2</sub> = 9.30 Hz, 1H, H-1'), 7.38 (d, 2H, Ar-H), 7.60 (m, 3H, Ar-H), 7.78 (m, 2H, Ar-H), 7.84 (s, 1H, pyridine H-5), 8.18 (d, 2H, Ar-H).                                     |
| <b>6k</b> | 3660-3200 (OH),<br>2220 (CN),<br>1620 (CO pyridone)                   | 3.31-3.78 (m, 6H, H-6', 6", H-5', H-4', H-3' and H-2'), 3.86 (s, 3H, OCH <sub>3</sub> ), 4.61 (t, 1H, 2'-OH), 5.18 (d, 1H, 3'-OH), 5.25 (s, 1H, 4'-OH), 5.50 (d, 1H, 6'-OH), 6.20 (d, J <sub>1,2</sub> = 8.58 Hz, 1H, H-1'), 7.11 (d, 2H, Ar-H), 7.60 (m, 3H, Ar-H), 7.70 (s, 1H, pyridine H-5), 7.81 (d, 2H, Ar-H), 8.05 (d, 2H, Ar-H).                                    |
| <b>6l</b> | 3650-3180 (OH, NH <sub>2</sub> ),<br>2220 (CN),<br>1620 (CO pyridone) | 3.28-3.87 (m, 6H, H-6', 6", H-5', H-4', H-3' and H-2'), 4.65 (t, 1H, 2'-OH), 5.12 (d, 1H, 3'-OH), 5.24 (s, 1H, 4'-OH), 5.48 (d, 1H, 6'-OH), 5.96 (s, 2H, NH <sub>2</sub> ), 6.21 (d, J <sub>1,2</sub> = 8.66 Hz, 1H, H-1'), 6.68 (d, 2H, Ar-H), 7.58 (m, 3H, Ar-H), 7.68 (s, 1H, pyridine H-5) 7.85 (m, 2H, Ar-H), 8.05 (d, 2H, Ar-H).                                      |
| <b>6a</b> | 3660-3200 (OH),<br>2222 (CN),<br>1625 (CO pyridone)                   | 2.40 (s, 3H, CH <sub>3</sub> ), 3.18-3.66 (m, 6H, H-6', 6", H-5', H-4', H-3' and H-2'), 4.62 (t, 1H, 2'-OH), 5.18 (d, 2H, 3'-OH and 4'-OH), 5.45 (s, 1H, 6'-OH), 6.15 (d, J <sub>1,2</sub> = 8.48 Hz, 1H, H-1'), 6.88 (m, 1H, furan H-4), 7.40 (d, 4H, Ar-H), 7.69 (d, 1H, furan H-3), 8.05 (s, 1H, pyridine H-5), 8.15 (d, 1H, furan H-5).                                 |
| <b>6p</b> | 3600-3200 (OH, NH <sub>2</sub> ),<br>2220 (CN),<br>1600 (CO pyridone) | 3.22-3.68 (m, 6H, H-6', 6", H-5', H-4', H-3' and H-2'), 4.58 (t, 1H, 2'-OH), 5.08 (d, 1H, 3'-OH), 5.17 (s, 1H, 4'-OH), 5.49 (d, 1H, 6'-OH), 5.90 (s, 2H, NH <sub>2</sub> ), 6.16 (d, J <sub>1,2</sub> = 8.55 Hz, 1H, H-1'), 6.74 (d, 2H, Ar-H), 6.88 (dd, 1H, furan H-4), 7.60 (d, 1H, furan H-3), 7.78 (s, 1H, pyridine H-5), 8.00 (d, 2H, Ar-H), 8.14 (d, 1H, furan H-5). |

signals at  $\delta$  61.7, 67.7, 67.9, 70.3 and 71.3 ppm were assigned to C-6', C-4', C-2', C-3' and C-5', respectively. On the other hand, the signal of the carbonyl carbon atom of aglycone appeared at  $\delta$  162.7 ppm and the nitrile carbon atom appeared at  $\delta$  115.1 ppm. The preparation of crystalline 1-( $\beta$ -D-glycopyranosyl)3-cyanopyridine-2-ones **6a-p** was achieved by removing the blocking acetyl groups on treatment with methanolic ammonia at 0°C. The structures of compounds **6** were established on the basis of elemental analyses and spectral data. Thus, the analytical data for **6f** revealed a molecular formula  $C_{23}H_{22}N_2O_7$  ( $m/z$  438). The  $^1H$ NMR spectra showed the anomeric proton as a doublet at  $\delta$  6.18 ppm ( $J_{1,2} = 9.3$  Hz) indicating the presence of only the  $\beta$ -configuration. The other six glucose protons appeared as a multiplet at  $\delta$  3.21-3.78 ppm, while the four hydroxy groups of the glucose moiety resonated at  $\delta$  4.63-5.48 ppm (exchangeable by  $D_2O$ ). The  $^{13}C$  NMR spectra was characterized by a signal at  $\delta$  96.8 ppm corresponding to the C-1' atom of  $\beta$ -D-glucopyranose. Another five signals at  $\delta$  60.6, 69.7, 72.9, 77.1 and 78.2 ppm were assigned to C-6', C-4', C-2', C-3' and C-5' of the glucose moiety, respectively. In summary, we have achieved a regiospecific synthesis of interesting 3-deazapyrimidine nucleosides by the reaction of pyridine-2(1*H*)-ones with  $\alpha$ -halomonosugars. These nucleosides can be utilized as an excellent starting materials for the synthesis of other carbohydrate derivatives.

#### Antiviral Activity:

The anti-HIV activity and cytotoxicity of some 3-cyano-4 and 6-disubstituted-2-pyridone glucosides and galactosides are shown in Table 1. Among these types of glycosides the 4-furyl-6(p-methylphenyl) glucoside **6f** turned out to be the most selective anti-HIV agent, followed by 4-phenyl-6(p-methylphenyl) galactosides **6j** and 4-furyl-6 (p-aminophenyl) glucose tetraacetate **5h**., while; 4-furyl-6-phenyl- and 4, 6-diphenyl-, 4-furyl-6 (p-methylphenyl)-, and 4-phenyl-6(p-methylphenyl) glucosides or galactosides were devoid any therapeutic index at the indicated concentration.

#### EXPERIMENTAL:

##### 1-(2,3,4,6-Tetra-*O*-acetyl- $\beta$ -D-glucopyranosyl)-3-cyanopyridine-2-ones; **5**

##### General Coupling Procedure:

To a solution of 2(1*H*)-pyridineones **3a-h** (0.01 mol) in aqueous potassium hydroxide (0.56 g, 0.01 mol, in 6 mL of distilled water) was added a solution of 2,3,4,6-tetra-*O*-acetyl- $\alpha$ -D-glucopyranosyl bromide **4** (4.521 g, 0.011 mol) in acetone (30 mL). The reaction mixture was stirred at room temperature until judged complete by TLC (8-12h), then evaporated under reduced pressure at 40°C and the residue washed with distilled water to remove the formed potassium bromide. The product was dried and crystallized from ethanol to afford colourless crystals (cf. Table 2).

##### 1-( $\beta$ -D-Glucopyranosyl)-3-cyanopyridine-2-ones; **6**

##### General Procedure for Nucleoside Deacylation:

Dry gaseous ammonia was passed through a solution of protected nucleosides **5** (0.5 gm) in dry methanol (20 mL) at 0°C for about 0.5 hour. The reaction mixture was then stirred at 0°C until judged complete by

TLC (20-24 h). The mixture was evaporated under reduced pressure at 40°C giving a solid residue which was crystallized from methanol to afford colourless crystals (cf. Table 2).

### Biological Procedure

The compounds **5a-p** and **6a-p** were dissolved in dimethyl sulfoxide then diluted 1:100 in cell culture medium before preparing serial half-Log<sub>10</sub> dilutions. T<sub>4</sub> Lymphocytes were added and after a brief interval HIV-1 is added, resulting in 1:200 final dilution of the compound. Uninfected cells with the compound serve as a toxicity control, and infected and uninfected cells without the compound serve as basic controls. Cultures are incubated at 37° in a 5% carbon dioxide atmosphere for 6 days. The tetrazolium salt, XTT, is added to all wells, and cultures are incubated to allow formazan color development by viable cells. Individual wells are analyzed spectrophotometrically to quantitate formazan production, and in addition are viewed microscopically for detection of viable cells and confirmation of protective activity. Drug-treated virus-infected cells are compared with drug-treated noninfected cells and with other appropriate controls on the same plate. Data are reviewed in comparison with other tests done at the same time and a determination about activity is made.

### Acknowledgements

The authors are greatly indebted to Dr. John P. Bader, Dr. V. L. Narayanan and Dr. Michael R. Boyd, AIDS Department and Drug Synthesis & Chemistry Branch of Health and Human Services, National Institutes of Health for their valuable in vitro anti-HIV activity and antitumor activities of our samples.

### REFERENCES

1. M.J. Robins, B.L. Currie, R.K. Robins and A. Bloch, *Proc. Am. Assoc. Cancer Res.*, **1969**, *10*, 73.
2. W.M. Shannon, G. Arnett, and F.M. Schabel, Jr., *Antimicrob. Agents Chemother.*, **1972**, *2*, 159.
3. M.J. Robins and A.S.K. Lee, *J. Med. Chem.*, **1975**, *18*, 1070.
4. A. Bloch, G. Dutschman, B. Currie, R.K. Robins and M.J. Robins, *J. Med. Chem.*, **1973**, *16*, 294.
5. R.R. Copp and V.E. Marquez, *J. Med. Chem.*, **1991**, *34*, 208.
6. G.E.H. Elgemeie, N.M. Fathy, L.M. Faddah and M.Y. Ebeid, *Arch. Pharm. (Weinheim)*, **1991**, *324*, 149.
7. G.E.H. Elgemeie, A.M. Elzanate and A.K. Mansour, *J. Chem. Soc. Perkin Trans. 1*, **1992**, 1073.
8. G.E.H. Elgemeie, H.A. Regaila and N. Shehata, *J. Chem. Soc. Perkin Trans. 1*, **1990**, 1267.
9. G.E.H. Elgemeie, A.M. Elzanate and A.K. Mansour, *Bull. Chem. Soc. Jpn.*, **1993**, *66*, 555.
10. G.E.H. Elgemeie and B.A. Hussain, *Tetrahedron*, **1994**, *50*, 199.
11. G.E.H. Elgemeie, A.M.E. Attia, D.S. Farag and S.M. Sherif, *J. Chem. Soc., Perkin Trans. 1*, **1994**, 3.
12. G.E.H. Elgemeie, H.A. Regaila and N. Shehata, *Sulfur Lett.*, **1989**, *9*, 253.

Received August 3, 1994

Accepted February 17, 1995